What Bioinduction does

Bioinduction is a UK-based med-tech company founded in 2005 that specializes in neuromodulation technology, principally developing deep brain stimulation (DBS) implantable pulse generators under the Picostim brand. The Picostim system comprises an implantable pulse generator (IPG), a patient controller with rechargeable hardware, and clinician-programmable stimulation parameters, targeting movement and neurological disorders including Parkinson's disease, essential tremor, dystonia, and epilepsy. The company subsequently extended into urology with the Amber-UI, a wearable neurostimulation device aimed at mixed urinary incontinence, broadening its therapeutic footprint across two distinct neurostimulation indications.

The Picostim platform is presented through Amber Therapeutics' DBS patient information portal, which publishes instructional videos on linking the patient controller, starting and adjusting stimulation, recharging, and changing programs, indicating the system is in clinical deployment with clinician-supported patients. A second-generation patient controller, with revised indicator lighting, menu symbols, and recessed cable connectors, is in active production relative to the original device, showing continued hardware iteration of the IPG ecosystem.

In September 2023, Bioinduction was acquired by Amber Therapeutics Ltd. and ceased operating as an independent entity. Funding history consists only of two small UK innovation grants totaling approximately $27,000 from SBRI Healthcare and Innovate UK in 2017 and 2018, with no disclosed equity rounds or commercial revenue prior to acquisition. Following the transaction, Bioinduction's Picostim and Amber-UI technologies are commercialized under Amber Therapeutics' infrastructure; detailed pricing, distribution channels, and segment-level revenue mechanics are not publicly disclosed.

Name

Bioinduction

Legal name

Bioinduction Ltd.

Website

https://bioinduction.com

Company type

Private

Founded year

2005

Operating status

Acquired

Headcount range

11–50 employees

Short description

Bioinduction is a UK-based neuromodulation company that developed the Picostim implantable deep brain stimulation system for Parkinson's disease, essential tremor, dystonia, and epilepsy, and the Amber-UI wearable device for mixed urinary incontinence. It was acquired by Amber Therapeutics in September 2023.

Ownership category

akta.pro rank

Product category

Neurostimulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

• Deep brain stimulation devices
• Implantable pulse generators
• Wearable neurostimulation devices
• Neuromodulation therapy hardware
• Neurostimulation medical devices

Headquarters

HQ city

Bristol

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations

Core offering

Bioinduction developed and manufactured neuromodulation medical devices, including the Picostim Implantable Pulse Generator (IPG) deep brain stimulation system for treating neurological conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy, and the Amber-UI wearable neurostimulation device targeting mixed urinary incontinence. Its core business was hardware design and delivery of neurostimulation systems intended for clinical use by neurosurgery teams and healthcare providers.

Product overview

Bioinduction was a UK-based med-tech company specializing in neurostimulation technology. Prior to its acquisition by Amber Therapeutics in September 2023, Bioinduction developed the Amber-UI wearable neurostimulation device aimed at treating conditions such as mixed urinary incontinence. The acquisition enabled Amber Therapeutics to strengthen its hardware capabilities and accelerate commercialization of neurostimulation therapies. The company's technology has been integrated into Amber Therapeutics' neuromodulation platform following the acquisition.

Differentiator

Problem solved

Functional benefit

Products and services

• Picostim IPG (Implantable Pulse Generator) Deep brain stimulation implantable pulse generator system designed for patients with neurological conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy. The system is used by neurosurgery teams and DBS clinicians who implant and program the device, and includes a patient controller for starting, stopping, adjusting stimulation, recharging, changing programs, and linking to the IPG.
• Amber-UI Wearable Neurostimulation Device A wearable neurostimulation device developed by Bioinduction targeting neuromodulation therapy for patients with mixed urinary incontinence. The device is part of Amber Therapeutics' neuromodulation platform and is being advanced toward commercialization using hardware capabilities acquired from Bioinduction.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Medtronic: Global leader in deep brain stimulation with the Activa PC and Activa RC systems, directly competing with Bioinduction's Picostim DBS platform across Parkinson's, essential tremor, dystonia, and epilepsy indications.
• Abbott: Markets the Infinity DBS system following its St. Jude Medical acquisition; competes head-to-head with Picostim in implantable neurostimulation for movement disorders.
• Boston Scientific: Offers the Vercise DBS system and is a direct DBS competitor; also active in spinal cord and deep brain stimulation, overlapping with Bioinduction's core implantable neurostimulation space.
• Axonics: Specializes in sacral and tibial neuromodulation for urinary and bowel dysfunction; a direct analogue to the Amber-UI wearable for mixed urinary incontinence, validating the commercial model Bioinduction's device is pursuing.
• Inspire Medical Systems: Implantable neurostimulator (hypoglossal nerve stimulation) treating obstructive sleep apnea; comparable to Bioinduction as an implantable neurostimulation company targeting chronic conditions via electrical stimulation.

Broad incumbents

• Nevro: Spinal cord stimulation (Senza) leader; operates in the same implantable neuromodulation category as Picostim but addresses chronic pain rather than movement disorders, making it a broader neuromodulation incumbent.

Emerging players

• Saluda Medical: Closed-loop spinal cord stimulation developer with the Evoke system; an emerging player in implantable neurostimulation, partially overlapping with Bioinduction's broader neuromodulation platform.
• SceneRay: China-based emerging DBS device company developing next-generation deep brain stimulation systems; partial overlap with Bioinduction's Picostim in the broader DBS category.

Regional players

• MicroPort Scientific: China-based manufacturer with a DBS product line; regional player in the Asian market that competes with Bioinduction's DBS technology in Asia-Pacific geographies.
• PINS Medical: Beijing PINS Medical produces DBS systems primarily for the Chinese market; comparable hardware competitor focused on a different geography than Bioinduction/Amber.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bioinduction-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioinduction